Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose afatinib in elderly EGFR-mutant non-small cell lung cancer
jRCTs041180055Phase 2Completed
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-free survival. Started Aug 2016; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041180055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180055.